Replies to post #337948 on Amarin Corp Plc (AMRN)

[ziploc_1]

The generics have not made the necessary investments in companies producing API and, for the next two years, will not be able to take much more of the market from Amarin than what they already have taken.

[Pharmacydude]

HP
If you want my take on what I predict will happen it is as follows:
At some time in July we will hear that V has been proven to reduce the intensity and duration of COVID from the Argentina Prepare-it 1&2 trials (4,000 pts) dually published in a significant journal. As a result many foreign countries will grant Emergency Access Authority to V and governments will buy bulk quantities directly from Amarin (like they did with Remdesivir). Amarin will announce “since we can not count on our legal and regulatory rights to be protected in the US market we are forced to secure our sales to EU, China, India, Brazil and other countries desperately in need of an effective Covid therapy. As a result we have sold our entire inventory abroad and will allow gV to meet the entire US market , or what little they will be able to provide. We at Amarin feel we have a global responsibility to do our best to help out in the global pandemic that has devastated the world. Enjoy the rancid gV US and F U Du!” “Please forward all future requests for information to the new owners of Vascepa at Pfizer World headquarters.”
But seriously, positive Covid data will change everything and supply will be the primary issue.